silmitasertib: Clinical Trials

6 trials of silmitasertib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 terminated, 1 unknown. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Recruiting 1, Terminated 1, Unknown 1
Phase 23Completed 1, Recruiting 1, Terminated 1

Follow silmitasertib: new trials by email Literature Review of silmitasertib trials Research Report on silmitasertib

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma
Phase 1 / Phase 2RecruitingMilton S. Hershey Medical Center1042024-10-302026-10-06
A Study of Silmitasertib (CX-4945) in Healthy Subject
CX-4945 - COVID-19
Phase 1CompletedSenhwa Biosciences, Inc.302022-11-282025-01-27
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
CX 4945 - Medulloblastoma, Childhood, Medulloblastoma Recurrent
Phase 1 / Phase 2TerminatedPediatric Brain Tumor Consortium212019-07-252026-10-19
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
CX-4945 - Carcinoma, Basal Cell
Phase 1CompletedSenhwa Biosciences, Inc.252019-04-162025-05-20
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
CX-4945, Cisplatin, Gemcitabine - Cholangiocarcinoma
Phase 1 / Phase 2CompletedSenhwa Biosciences, Inc.1272014-06-012021-10-22
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
CX-4945 - Multiple Myeloma
Phase 1UnknownCylene Pharmaceuticals222010-09-012011-06-15

Conditions studied

Bile Duct Neoplasms (1)  ·  Biliary Tract Neoplasms (1)  ·  COVID-19 (1)  ·  Carcinoma, Basal Cell (1)  ·  Cholangiocarcinoma (1)  ·  Liposarcoma (1)  ·  Medulloblastoma (1)  ·  Microphthalmia, Isolated, with Coloboma 5 (1)  ·  Multiple Myeloma (1)  ·  Neuroblastoma (1)  ·  Osteosarcoma (1)  ·  Plasmacytoma (1)  ·  Rhabdomyosarcoma (1)  ·  Sarcoma, Ewing (1)

Sponsors

Senhwa Biosciences, Inc. (3)  ·  Cylene Pharmaceuticals (1)  ·  Milton S. Hershey Medical Center (1)  ·  Pediatric Brain Tumor Consortium (1)

Countries

United States (5)  ·  Taiwan (2)  ·  Canada (1)  ·  South Korea (1)

Top investigators

Chandrika Behura, MD (1)  ·  Jason Huang, MD (1)  ·  Jin-Ding Huang, PhD (1)  ·  Mitesh Borad, M.D. (1)  ·  Ralph Salloum, MD (1)

NIH funding

UM1CA081457 (1)